Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver DiseaseSJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82024-04-010OAAI
Identification of farnesoid X receptor β as a novel mammalian nuclear receptor sensing lanosterolMOLECULAR AND CELLULAR BIOLOGYIF2.72023-03-27171OAAI
Targeting the IDO1-Kynurenine-AhR pathway for cancer immunotherapyCANCER RESEARCHIF16.62019-07-015PRE
LXR inverse agonists reduce steatosis and fibrosis in the STAM mouse model but also improve insulin sensitivity in a high fat diet mouse clamp studyJOURNAL OF HEPATOLOGYIF332019-04-010PREAI
Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulationHEPATOLOGY INTERNATIONALIF6.12018-04-128PREAI
LXR inverse agonists inhibit de novo lipogenesis and reduce intestinal lipid and cholesterol absorption in a NAFLD mouse modelJOURNAL OF HEPATOLOGYIF332018-04-010PREAI
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunctionJOURNAL OF HEPATOLOGYIF332017-04-01134OAAI
The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancerONCOGENEIF7.32017-03-2063PREAI
Anti-steatotic effects in conjunction with lowering of PNPLA3 mRNA exerted by LXR inverse agonists in human hepatocytes and in rodent models of non-alcoholic fatty liver diseaseJOURNAL OF HEPATOLOGYIF332017-01-010PREAI
FROM MICE TO MEN - CHANGES IN FGF15/19 EXPRESSION AND BILE ACID LEVELS AS SENSITIVE MARKERS OF PHARMACOLOGICAL FXR ACTIVATION; RESULTS FROM HUMAN PHASE I AND ANIMAL STUDIES USING THE POTENTAND SELECTIVE FXR AGONIST PX-102JOURNAL OF HEPATOLOGYIF332016-01-010PREAI
EFFECTS OF FXR AGONIST PX20606 ON TUMOUR FORMATION IN ANIMAL MODELS OF NON-ALCOHOLIC FATTY LIVER DISEASEJOURNAL OF HEPATOLOGYIF332015-04-010PREAI
Reprogramming of the ERRα and ERα Target Gene Landscape Triggers Tamoxifen Resistance in Breast CancerCANCER RESEARCHIF16.62015-02-1534OAAI
The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoproteinINTERNATIONAL JOURNAL OF CANCERIF4.72014-11-1317OAAI
Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (-/-) MiceJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82012-12-01110OAAI
FXR AGONISTS PREVENT STEATOSIS, HEPATOCYTE DEATH AND PROGRESSION OF NASH TOWARDS HCC IN A HYPOINSULINAEMIC MOUSE MODEL OF PROGRESSIVE LIVER DISEASEJOURNAL OF HEPATOLOGYIF332012-04-010PREAI
FXR DIRECTLY CONTROLS THE TUMOR SUPPRESSOR NDRG2 AND FXR AGONISTS REDUCE TUMOR GROWTH AND METASTASIS IN AN ORTHOTOPIC XENOGRAFT MOUSE MODELJOURNAL OF HEPATOLOGYIF332012-04-011PREAI
NOVEL FXR AGONISTS WITH POTENT LIPID LOWERING, INSULIN SENSITISING, ANTI-INFLAMMATORY AND ANTI-FIBROTISATION EFFECTS IN MOUSE MODELS OF METABOLIC SYNDROME AND NASHJOURNAL OF HEPATOLOGYIF332011-03-013PREAI
Estrogen-Related Receptor α Expression and Function Is Associated with the Transcriptional Coregulator AIB1 in Breast CarcinomaCANCER RESEARCHIF16.62009-06-1533OAAI
Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulatorsDRUG DISCOVERY TODAYIF7.52007-10-0119PREAI
A novel principle for partial agonism of liver X receptor ligands - Competitive recruitment of activators and repressorsJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92006-02-0189OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向